List of Excipients in Branded Drug BORTEZOMIB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	BORTEZOMIB	bortezomib	0409-1703	MANNITOL
DrReddy's Laboratories Inc	BORTEZOMIB	bortexomib	43598-865	ANHYDROUS CITRIC ACID
DrReddy's Laboratories Inc	BORTEZOMIB	bortexomib	43598-865	TROMETHAMINE

Generic Drugs Containing BORTEZOMIB

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	bortezomib	0143-9098	MANNITOL
Hospira Inc	bortezomib	0409-1700	MANNITOL
Sandoz Inc	bortezomib for injection	0781-3258	MANNITOL

What are the Most Frequently-Used Excipients in BORTEZOMIB?

# Of NDCs	Excipient
31	MANNITOL
1	TERT-BUTYL ALCOHOL

Bortezomib Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Bortezomib is an established injectable proteasome inhibitor with a mature generic market and limited remaining value in the active pharmaceutical ingredient itself. The strongest commercial opportunities are in excipient-enabled improvements: room-temperature stability, ready-to-use presentations, lower preparation burden, reduced vial waste, safer handling, and alternative delivery systems. The reference product, Velcade, uses a simple lyophilized formulation containing bortezomib and mannitol. That simplicity leaves room for formulation differentiation, but regulatory and patent barriers increase sharply for products that change route, dose, release profile, or clinical performance.

What is the current bortezomib formulation?

The reference bortezomib product is Velcade, marketed by Millennium Pharmaceuticals and later Takeda. It is supplied as a sterile, preservative-free lyophilized powder for intravenous or subcutaneous administration.

Attribute	Velcade formulation
Active ingredient	Bortezomib
Dosage form	Lyophilized powder for injection
Vial strengths	1 mg and 3.5 mg
Primary excipient	Mannitol
Preservatives	None
Reconstitution diluent	0.9% sodium chloride injection
IV concentration after reconstitution	1 mg/mL
Subcutaneous concentration after reconstitution	2.5 mg/mL
Product pH after reconstitution	Approximately 3.5 to 4.0
Storage before reconstitution	Controlled room temperature
Administration	Intravenous or subcutaneous
FDA reference product	NDA 021602

Each 3.5 mg vial contains 3.5 mg bortezomib and 35 mg mannitol. The product is reconstituted immediately before administration and has no antimicrobial preservative. The label imposes preparation controls because dosing errors and route-specific concentration differences can cause serious toxicity.[1]

Bortezomib is a boronic acid-containing small molecule with formulation sensitivity related to aqueous stability, pH, oxidation, adsorption, and concentration. Mannitol is not only a bulking agent. In the lyophilized product, it supports cake structure and physical stability and is part of the established formulation profile.

What excipients are most relevant to bortezomib development?

Mannitol remains the lowest-risk benchmark, but several excipient classes can support differentiated products.

Mannitol

Mannitol is the reference excipient and has a strong regulatory precedent in bortezomib injection. It provides bulking capacity during lyophilization and can support a visually acceptable cake. A generic product using mannitol has the advantage of a known formulation platform and limited excipient novelty.

Commercial limitations include:

• dependence on lyophilization;
• reconstitution time;
• vial overfill and unused-dose waste;
• possible crystallization behavior during freeze-drying;
• limited differentiation from existing generics.

A mannitol-based formulation can still create value if it improves cake robustness, reconstitution time, container closure compatibility, or stability after reconstitution.

Sugars and polyols

Sucrose, trehalose, sorbitol, and related polyols may be evaluated as bulking or stabilizing excipients. Their value depends on the specific freeze-drying cycle and the physical state of the active ingredient.

Trehalose and sucrose can improve amorphous matrix formation, but they may create a less favorable cake or higher residual moisture profile than mannitol. Sorbitol can present crystallization and glass-transition challenges. A switch away from mannitol therefore requires comparative data on:

• potency;
• related substances;
• moisture;
• reconstitution time;
• cake collapse;
• visible and subvisible particles;
• container interaction;
• post-reconstitution stability.

These excipients are most commercially relevant when used in a ready-to-use liquid or a more stable concentrated formulation, not merely as a substitute for mannitol in a conventional lyophilized vial.

Buffers and pH modifiers

Bortezomib formulations require controlled pH because degradation and solubility can change materially across the pH range. Potential buffer systems include citrate, phosphate, acetate, and histidine, but the reference product's acidic formulation limits the practical design space.

A buffer strategy must account for:

• boronic acid chemistry;
• hydrolysis and oxidation;
• precipitation after dilution;
• compatibility with infusion materials;
• local tolerability after subcutaneous injection;
• pH drift during storage;
• interaction with mannitol or other polyols.

A low-buffer or self-buffering formulation can have commercial value if it improves stability without introducing a new excipient burden. A buffered formulation that enables ready-to-use storage may support a stronger product story than a conventional excipient substitution.

Surfactants

Polysorbates, poloxamers, and related surfactants may reduce interfacial adsorption and agitation-related particulate formation. Their use must be balanced against oxidation, peroxide impurities, extractables, and immunogenicity concerns associated with some surfactant systems.

Surfactants are most relevant to:

• concentrated liquid presentations;
• prefilled syringes;
• cartridge systems;
• transport-stressed products;
• low-volume subcutaneous delivery.

They offer a plausible formulation patent position when tied to a defined concentration range, container, stability profile, or delivery device. A generic addition of a surfactant without a measurable product benefit is unlikely to create durable commercial differentiation.

Chelators and antioxidants

EDTA, methionine, ascorbate, and other stabilizing agents may be screened where trace metals or oxidative pathways contribute to degradation. These excipients require careful toxicological and compatibility review. A chelator or antioxidant can be useful in a liquid formulation, but the patentability of a simple stabilizer addition is usually weaker than a formulation that achieves a material improvement in shelf life or administration.

Tonicity agents

Sodium chloride and other tonicity modifiers may be needed for a ready-to-use subcutaneous product. The formulation must control injection volume and local tolerability. The Velcade label uses different reconstituted concentrations for intravenous and subcutaneous administration, which creates a practical opportunity for a presentation designed specifically for subcutaneous use.[1]

What excipient strategy is most commercially attractive?

The highest-value strategy is a ready-to-use or simplified-use product that reduces preparation risk without compromising stability.

Strategy	Commercial value	Regulatory complexity	Likely differentiation
Mannitol-based lyophilized generic	Low to moderate	Low	Low
Faster-reconstituting lyophilized vial	Moderate	Low to moderate	Moderate
Dual-use IV/SC kit	Moderate	Moderate	Moderate
Ready-to-use liquid injection	High	Moderate to high	High
Prefilled SC syringe	High	High	High
Extended post-reconstitution stability	Moderate to high	Moderate	Moderate
Long-acting depot formulation	Very high	High	Very high
Oral bortezomib formulation	High	High	Very high
Combination product with another myeloma agent	High	High	High

Ready-to-use liquid formulation

A stable liquid bortezomib injection could eliminate reconstitution, reduce pharmacy labor, and reduce dosing errors. The main technical barriers are chemical stability, precipitation, adsorption, oxidation, container closure compatibility, and preservative strategy.

A commercially credible liquid formulation would need to demonstrate:

• a shelf life comparable to the lyophilized product;
• low particulate burden;
• acceptable stability across shipping temperatures;
• compatibility with vial, syringe, or cartridge materials;
• acceptable post-opening or post-puncture handling;
• no clinically meaningful change in injection tolerability.

The commercial opportunity is strongest in hospitals, outpatient infusion centers, and specialty pharmacies where preparation time and medication safety have measurable economic value.

Prefilled subcutaneous presentation

Subcutaneous bortezomib is already an established route. A prefilled syringe or cartridge could reduce preparation steps and concentration-selection errors. The product would need to address viscosity, injection force, needle compatibility, dose flexibility, and stability under device storage conditions.

A prefilled presentation may support a 505(b)(2) strategy if it changes the delivery system or product characteristics in a way that requires reliance on the reference product's safety and efficacy data. The regulatory pathway would depend on the degree of change and the applicable FDA requirements.[2]

Extended in-use stability

Bortezomib is often prepared in advance for scheduled treatment. A formulation with longer stability after reconstitution could reduce pharmacy waste and improve workflow. This opportunity may be achievable without changing the active ingredient or route.

The strongest claims would relate to a defined combination of:

• excipient composition;
• concentration;
• container;
• storage temperature;
• protection from light;
• maximum in-use period;
• potency and impurity limits.

What formulation patents could protect bortezomib products?

Formulation patents can protect the composition, manufacturing process, container, device, or use conditions. The strongest patent positions normally require more than the presence of a conventional excipient.

Potential formulation claim categories

1. A liquid bortezomib formulation with defined pH, buffer, stabilizer, and concentration ranges.
2. A lyophilized composition with a specified excipient ratio and residual-moisture profile.
3. A formulation with defined post-reconstitution stability.
4. A prefilled syringe or cartridge containing a stable bortezomib solution.
5. A formulation that reduces injection-site pain or local irritation.
6. A concentrated subcutaneous formulation that reduces injection volume.
7. A depot or sustained-release formulation.
8. A container closure system that limits adsorption or extractables.
9. A manufacturing process that improves impurity control or lyophilization uniformity.
10. A combination of bortezomib with a delivery device or administration protocol.

A patent based only on substituting sucrose for mannitol may face obviousness and enablement challenges. A stronger position would link the excipient choice to unexpected stability, reduced degradation, improved delivery, or a clinically relevant administration benefit.

When did bortezomib lose exclusivity?

Bortezomib's principal small-molecule exclusivity period has ended, and generic injectable products have entered the U.S. market. Velcade was approved by FDA in 2003, and its original regulatory exclusivity and principal patent barriers have expired. FDA approved the first generic bortezomib injection in 2017.[3]

Milestone	Date or status
FDA approval of Velcade	May 13, 2003
Initial indication	Multiple myeloma
U.S. composition and formulation patent disputes	Primarily historical
First FDA-approved generic bortezomib injection	2017
Current market structure	Generic injectable competition
Biosimilar pathway	Not applicable

Exact patent expiration and Orange Book listing status should be evaluated by patent number, terminal disclaimer, patent-term adjustment, pediatric exclusivity, and any litigation settlement. Patent rights may differ by jurisdiction and by claim type. FDA's Orange Book and Drugs@FDA records remain the controlling regulatory sources for listed patents and approved product information.[3,4]

What is the Orange Book status of bortezomib?

Bortezomib is a small-molecule drug, so its U.S. regulatory reference is the Orange Book rather than the Purple Book. The relevant reference product is Velcade injection under NDA 021602.

The Orange Book analysis should separate:

• active ingredient patents;
• formulation patents;
• method-of-use patents;
• device or presentation claims;
• patents that are no longer listed;
• patents subject to pediatric exclusivity;
• patents challenged through an Abbreviated New Drug Application.

For generic bortezomib injection, the principal legal pathway has been ANDA approval with paragraph IV certification against listed patents where applicable. Because generic products are already marketed, the practical patent question has shifted from blocking ordinary injectable entry to protecting differentiated formulations and delivery systems.

Which companies are challenging or competing with Velcade?

The relevant competition is divided between generic bortezomib manufacturers and alternative multiple myeloma therapies.

Generic injectable competition

Generic manufacturers have competed on price, supply reliability, hospital contracting, and vial economics. Manufacturers and applicants have included major generic pharmaceutical companies, although product availability varies by country and over time.

The commercial market is sensitive to:

• contract pricing;
• backorder history;
• oncology distributor access;
• vial sizes;
• hospital formulary position;
• availability of subcutaneous administration;
• manufacturing-site reliability.

Alternative proteasome inhibitors

Drug	Active ingredient	Route	Commercial implication
Velcade and generics	Bortezomib	IV/SC	Low-cost established standard
Kyprolis	Carfilzomib	IV	Competes in relapsed disease; higher treatment complexity
Ninlaro	Ixazomib	Oral	Competes through oral convenience
Darzalex	Daratumumab	IV/SC	Competes through anti-CD38 mechanism
Empliciti	Elotuzumab	IV	Combination-based competition

Ixazomib creates the clearest delivery-system comparison because it offers an oral proteasome inhibitor. Bortezomib's formulation opportunity is therefore tied to reducing the inconvenience of injectable administration rather than attempting to compete solely on active ingredient price.[5]

Are biosimilar risks relevant to bortezomib?

No. Bortezomib is a chemically synthesized small molecule, not a biologic. Biosimilar approval under the Public Health Service Act does not apply.

The competitive risk comes from:

• ANDA-approved generic injections;
• 505(b)(2) reformulations;
• alternative proteasome inhibitors;
• oral or long-acting delivery systems;
• hospital purchasing consolidation.

A bortezomib product with a new route, device, or release profile may face a more complex regulatory pathway than a conventional generic, but it would not be a biosimilar.

What FDA regulatory pathways apply to new bortezomib formulations?

ANDA

An ANDA is appropriate for a product that is pharmaceutically equivalent and bioequivalent to the reference product and does not rely on clinically meaningful formulation or delivery changes. This is the lowest-risk route for a conventional mannitol-based generic injection.

505(b)(2) NDA

A 505(b)(2) application may be appropriate for a new formulation, delivery system, concentration, route, or presentation that relies partly on FDA's prior findings for Velcade. The sponsor must address the new product's safety, efficacy, quality, and any required bridging studies.

Potential 505(b)(2) opportunities include:

• ready-to-use liquid bortezomib;
• prefilled subcutaneous injection;
• new concentration;
• reduced-volume administration;
• extended in-use stability;
• depot delivery;
• combination presentation.

New drug application

A product with a new clinical role, new route, or substantial pharmacokinetic change may require a full NDA package. An oral or sustained-release bortezomib product would likely require meaningful clinical development unless the sponsor can establish a narrower reliance strategy.

How strong is the patent estate for bortezomib excipients?

The core bortezomib patent estate is commercially mature. The stronger remaining opportunity is not basic composition-of-matter protection but product-specific formulation and device IP.

IP category	Strength for a new entrant
Bortezomib molecule	Weak because core rights have expired
Mannitol lyophilized formulation	Weak to moderate
New liquid formulation	Moderate to strong if stability is unexpected
Prefilled syringe	Moderate, dependent on device and formulation claims
Extended in-use stability	Moderate if supported by robust data
Depot formulation	Stronger, but high development risk
Manufacturing process	Moderate if impurity or yield improvement is demonstrated
Method of use	Narrow and indication-dependent
Combination product	Moderate to strong, but clinically complex

Patent durability depends on claim scope, priority dates, written description, enablement, obviousness, and freedom to operate around existing patents. Trade secrets may be more valuable than patents for lyophilization cycles, impurity-control methods, and scale-up parameters.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is not synthesis of bortezomib. It is reliable sterile production and control of the finished dosage form.

Key barriers include:

• containment of a potent cytotoxic drug;
• aseptic processing;
• lyophilization cycle development;
• control of residual moisture;
• prevention of adsorption and particulate formation;
• compatibility with elastomeric closures;
• extractables and leachables;
• stability-indicating analytical methods;
• vial fill accuracy;
• consistent reconstitution;
• operator safety during preparation.

A supplier that provides a qualified excipient system, lyophilization cycle, container closure, and analytical package can capture more value than a commodity excipient vendor. The commercial proposition should be built around reduced total cost of ownership, not only excipient price.

What licensing deals and partnership opportunities exist?

Bortezomib's principal commercial rights have been associated with Millennium Pharmaceuticals and Takeda. For new formulations, partnership structures are more likely to involve:

• excipient suppliers;
• contract development and manufacturing organizations;
• prefilled syringe or cartridge manufacturers;
• oncology specialty distributors;
• generic manufacturers seeking differentiated products;
• hospital systems seeking lower preparation burden.

The most practical licensing asset would be a formulation platform with demonstrated stability, scalable manufacturing, and a defined regulatory pathway. A patent application alone is less attractive than a package containing formulation composition, process parameters, container data, and pilot stability.

What revenue exposure exists for a bortezomib formulation product?

Revenue exposure is concentrated in multiple myeloma and related hematologic malignancies. Bortezomib is used in frontline and relapsed multiple myeloma and in mantle cell lymphoma. The principal value drivers are treatment volume, generic price erosion, hospital purchasing contracts, and the ability to support outpatient administration.

A differentiated product can command a premium only if it produces a measurable economic or clinical benefit:

• less pharmacy preparation;
• lower medication-error risk;
• reduced vial waste;
• fewer cold-chain requirements;
• longer in-use stability;
• improved subcutaneous tolerability;
• lower injection volume;
• easier home or outpatient administration.

A conventional generic formulation has limited pricing power. A ready-to-use or device-enabled product can support a higher margin, but the sponsor must fund formulation, device, human-factors, stability, and regulatory development.

What generic launch scenarios exist for bortezomib?

Low-cost conventional generic

This scenario uses the established lyophilized injection format and competes through price and supply. It has the lowest development risk but faces the strongest commoditization.

Premium generic with preparation advantages

This product retains the injectable route but improves reconstitution time, stability, packaging, or dose handling. It can compete for hospital contracts without requiring a new clinical positioning.

505(b)(2) ready-to-use product

This scenario targets outpatient centers and specialty pharmacies. The product may obtain protection through formulation, device, and process patents, but its clinical and CMC requirements are higher.

Long-acting or oral product

This scenario offers the highest potential differentiation and the highest development risk. It competes directly with ixazomib and may require new pharmacokinetic, safety, and efficacy evidence.

Key Takeaways

• Velcade uses a simple preservative-free lyophilized formulation containing bortezomib and mannitol.
• Conventional bortezomib injection is a mature generic market; molecule-level exclusivity is no longer the main barrier.
• The strongest excipient opportunity is a stable ready-to-use or prefilled subcutaneous formulation.
• Mannitol is the lowest-risk benchmark, but it provides limited differentiation by itself.
• Liquid formulations require control of pH, oxidation, precipitation, adsorption, particulates, and container compatibility.
• Bortezomib has no biosimilar exposure because it is a small molecule.
• New formulations may use an ANDA or 505(b)(2) pathway depending on the degree of change.
• Formulation patents are strongest when linked to unexpected stability, reduced injection burden, improved device performance, or a defined in-use period.
• Manufacturing know-how may be more valuable than broad excipient claims in a mature generic market.
• Commercial success depends on reducing pharmacy labor, medication errors, vial waste, or administration burden.

FAQs

Can bortezomib be formulated as a ready-to-use injection?

Yes. A ready-to-use product is technically plausible, but it must establish adequate chemical and physical stability, low particulate levels, container compatibility, and an acceptable regulatory bridge to Velcade.

Is mannitol essential to bortezomib injection?

No. Mannitol is the reference excipient and provides a low-risk benchmark, but alternative sugars, polyols, buffers, and stabilizers may be evaluated if they provide a documented formulation benefit.

Can an excipient supplier patent a bortezomib formulation?

Yes. Patent protection may cover a defined composition, concentration, pH, excipient ratio, stability profile, container, device, or manufacturing process. Generic substitution alone is less likely to support strong claims.

Would a prefilled bortezomib syringe qualify as a generic?

Not necessarily. If the presentation changes the formulation, concentration, device, or administration characteristics, the product may require a 505(b)(2) NDA rather than a conventional ANDA.

Which bortezomib opportunity has the best risk-adjusted profile?

A differentiated injectable product with extended post-reconstitution stability, lower preparation burden, or a prefilled subcutaneous presentation has a better risk-adjusted profile than an oral or long-acting product, which would require broader clinical and regulatory development.

References

1. U.S. Food and Drug Administration. (2023). Velcade (bortezomib) for injection prescribing information. Millennium Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (2017). FDA approves first generic bortezomib for injection. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. National Cancer Institute. (2024). Multiple myeloma treatment: Health professional version. National Institutes of Health.